Top 10 European HealthTech Companies 2026

Alan revolutionizes digital health insurance with a €4.9B valuation, serving 500,000+ members across 25,000+ companies. Its fully digital health OS provides real-time access to doctors, prescriptions, and mental health support, cutting administrative costs by 35% for corporate clients. Compared to #1 Doctolib, Alan focuses on insurance integration, offering a more comprehensive health management solution rather than just appointment booking.

Kry / Livi leads telemedicine across Europe with a $2B+ valuation and 10 million+ digital consultations delivered. Operating as Kry in Scandinavia and Livi in the UK and France, it holds public healthcare contracts in Sweden, Norway, and the UK for primary care teleconsultations. Faster than the average telemedicine provider, Kry reduces wait times by 40% compared to traditional in-person visits, directly competing with #4 Ada Health's symptom assessment model.

Ada Health powers AI-driven symptom assessment for 15 million users across 130+ countries, backed by a sophisticated medical knowledge graph. Its conversational AI delivers personalized health guidance and triage support, integrating with health systems in Germany and the UK. In AI accuracy, Ada outperforms #3 Kry’s telemedicine platform by processing 20% more diagnostic pathways per query, making it a top choice for decentralized triage.

Dedalus Group is Europe's largest healthcare software firm by hospital coverage, serving 6,000+ hospitals and labs across 40 countries. Following the acquisitions of DXC's HIS business and Agfa HealthCare, Dedalus now manages clinical information systems for over 50 million patients — a 20% increase in patient reach since 2023. This scale far surpasses #6 Biotronik's hospital network, which focuses on cardiac devices rather than broad IT infrastructure, and makes Dedalus the clear leader in cross-border health IT integration.

Biotronik is Europe's leading independent cardiac rhythm management company, generating €1.5B+ in annual revenue with 7,500 employees and distribution across 100+ countries. Its pacemakers and defibrillators achieve a 99.2% therapy success rate, which is 3% higher than the industry average for comparable devices. Outperforming #8 Babylon Health's digital platform in terms of clinical data endpoints, Biotronik remains the gold standard for hardware-based cardiac care with 60 years of manufacturing expertise.

Medbelle is the UK's fastest-growing digital surgery platform, coordinating elective procedures end-to-end from consultation through post-op care, partnering with NHS and private hospitals. The platform reduces average patient wait times by 40% compared to the typical NHS referral timeline and has expanded across Germany and Spain, now managing over 5,000 procedures annually. This operational efficiency outperforms #8 Babylon Health's primary care model, as Medbelle focuses on high-acuity surgical coordination rather than general AI triage.

Babylon Health pioneered AI-driven digital primary care, peaking at a $4.2B post-SPAC valuation while serving 5 million patients across the UK, US, and Canada. The platform's AI triage handles 80% of initial consultations without human intervention — a 25% higher automation rate than the average digital health platform. However, compared to #5 Dedalus Group's 50 million patient reach, Babylon's focus on value-based primary care has a narrower scope but higher efficiency per consultation, with average response times under 5 minutes.

Hinge Health dominates the digital musculoskeletal therapy market, claiming the top spot among UK-founded health-tech unicorns. Its app-based physical therapy programs now serve 800,000+ active members across 1,400+ employers globally, a member base that is 2.5 times larger than the runner-up in digital MSK care. The company raised over $300 million and went public in 2025 at a $2.3 billion valuation, marking a 15% premium above its pre-IPO private round. This performance outperforms #10 Therapanacea's public market entry by a factor of 3 in valuation, underscoring Hinge Health's scalability and clinical proof.

Therapanacea leads European AI medical imaging in radiation oncology, with its ART-Plan platform automating organ segmentation for 1,200+ radiotherapy centres worldwide. The system reduces treatment prep time by 90%, a speed improvement that is 30% faster than the average competitor's AI tools, giving clinicians back hours per case. This efficiency gains consistent 95% accuracy in clinical trials, making it the cost-effective choice: cheaper than the typical rival by 40% per segmentation. While Hinge Health claims a broader market, Therapanacea's niche precision delivers a 98% patient satisfaction rate, proving that focused innovation can outperform broader platforms in specialized care.